Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cytotect FH for prevention of congenital cytomegalovirus infection in pregnancy
2007-004692-19Phase 3Completed
- Sponsor
- Biotest AG
- Start
- Sep 2007
- Modality
- IgG Antibodies → Naked Antibodies → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of human cytomegalovirus immune globulin in congenital cytomegalovirus infection (cCMV) (2 arms), sponsored by Biotest AG. Primary endpoint: Congenital CMV infection in newborns or fetuses. Started Sep 2007; status: completed.
02
Drugs
human cytomegalovirus immune globulin
03
Conditions
congenital cytomegalovirus infection (cCMV)
Beyond the preview
Go deeper on 2007-004692-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-004692-19.